BRPI0504945B8 - Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. - Google Patents
Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.Info
- Publication number
- BRPI0504945B8 BRPI0504945B8 BRPI0504945A BRPI0504945A BRPI0504945B8 BR PI0504945 B8 BRPI0504945 B8 BR PI0504945B8 BR PI0504945 A BRPI0504945 A BR PI0504945A BR PI0504945 A BRPI0504945 A BR PI0504945A BR PI0504945 B8 BRPI0504945 B8 BR PI0504945B8
- Authority
- BR
- Brazil
- Prior art keywords
- flavivirus
- virus
- heterologous
- recombinant
- nucleotide sequences
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0504945A BRPI0504945B8 (pt) | 2005-10-31 | 2005-10-31 | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
US12/084,387 US8828687B2 (en) | 2005-10-31 | 2006-10-31 | Method for the production of recombinant virus, DNA constructs, recombinant virus and vaccine compositions |
PCT/BR2006/000237 WO2007051267A2 (en) | 2005-10-31 | 2006-10-31 | Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions |
EP06804595.4A EP1989316B1 (en) | 2005-10-31 | 2006-10-31 | Method for the production of recombinant flavivirus, DNA constructs, recombinant flavivirus and vaccine compositions |
US14/304,387 US9539317B2 (en) | 2005-10-31 | 2014-06-13 | Method for the production of recombinant virus, DNA constructs, recombinant virus and vaccine compositions |
US15/378,294 US10286059B2 (en) | 2005-10-31 | 2016-12-14 | Method for the production of recombinant virus, DNA constructs, recombinant virus and vaccine compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0504945A BRPI0504945B8 (pt) | 2005-10-31 | 2005-10-31 | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0504945A BRPI0504945A (pt) | 2007-08-07 |
BRPI0504945A8 BRPI0504945A8 (pt) | 2015-12-22 |
BRPI0504945B1 BRPI0504945B1 (pt) | 2021-06-08 |
BRPI0504945B8 true BRPI0504945B8 (pt) | 2022-08-02 |
Family
ID=38006220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0504945A BRPI0504945B8 (pt) | 2005-10-31 | 2005-10-31 | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
Country Status (4)
Country | Link |
---|---|
US (3) | US8828687B2 (pt) |
EP (1) | EP1989316B1 (pt) |
BR (1) | BRPI0504945B8 (pt) |
WO (1) | WO2007051267A2 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2448971C (en) | 2001-06-01 | 2013-11-26 | Acambis, Inc. | Chimeric flavivirus vectors |
EP2295023A1 (en) | 2002-01-15 | 2011-03-16 | Sanofi Pasteur Biologics Co. | Flavivirus vaccines |
BRPI0316346B1 (pt) | 2002-11-15 | 2016-05-31 | Acambis Inc | molécula de ácido nucleico, flavivírus quimérico, uso do referido flavivírus e método de fabricação de vacina de flavivírus quimérico contra vírus do nilo ocidental |
BRPI0504945B8 (pt) | 2005-10-31 | 2022-08-02 | Fundacao Oswaldo Cruz | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
CA2676719A1 (en) * | 2007-02-09 | 2008-08-21 | Sanofi Pasteur Biologics Co. | Viral vectors and methods of use |
GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
EP2408477A4 (en) * | 2009-03-16 | 2013-03-27 | Sanofi Pasteur Biologics Llc | REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS |
BRPI0914507A2 (pt) * | 2009-12-23 | 2012-04-10 | Fundacao Oswaldo Cruz | vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela |
BR102016018430A2 (pt) * | 2016-08-10 | 2018-02-27 | Fundação Oswaldo Cruz | Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivírus e/ou outros patógenos. |
SG11201908280SA (en) | 2017-03-30 | 2019-10-30 | Univ Queensland | "chimeric molecules and uses thereof" |
EP4400174A2 (en) | 2017-09-01 | 2024-07-17 | The Francis Crick Institute Limited | Immunoregulatory molecules and uses therefor |
GB201814563D0 (en) * | 2018-09-07 | 2018-10-24 | Univ Leuven Kath | Chimeric flavivirus lyssavirus vaccines |
KR20220008317A (ko) * | 2019-05-15 | 2022-01-20 | 코다제닉스 인코포레이티드 | 약독화된 황열병 바이러스 및 암 치료를 위한 그의 용도 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE297757T1 (de) * | 1997-02-28 | 2005-07-15 | Acambis Inc | Chimäre impfstoffe gegen flaviviren |
BRPI9701774B8 (pt) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
CA2311395C (en) * | 1997-11-28 | 2006-11-28 | The Crown In The Right Of The Queensland Department Of Health | Flavivirus expression and delivery system |
AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
US6589531B1 (en) * | 2000-01-21 | 2003-07-08 | The Regents Of The University Of California | Recombinant yellow fever virus and method of use thereof |
KR100710519B1 (ko) * | 2002-10-09 | 2007-04-24 | (주)씨아이디 | 일본뇌염 바이러스의 신규한 전체-길이의 게놈 RNA 및상기 JEV 게놈 RNA에 대한 감염성이 있는 JEVcDNA 및 이것의 용도 |
WO2005040390A1 (fr) * | 2003-07-21 | 2005-05-06 | Shanghai Tengen Biomedical Co., Ltd. | Vaccin recombine utilisant le virus de la fievre jaune comme vecteur |
BRPI0504945B8 (pt) | 2005-10-31 | 2022-08-02 | Fundacao Oswaldo Cruz | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
-
2005
- 2005-10-31 BR BRPI0504945A patent/BRPI0504945B8/pt active Search and Examination
-
2006
- 2006-10-31 WO PCT/BR2006/000237 patent/WO2007051267A2/en active Application Filing
- 2006-10-31 EP EP06804595.4A patent/EP1989316B1/en active Active
- 2006-10-31 US US12/084,387 patent/US8828687B2/en active Active
-
2014
- 2014-06-13 US US14/304,387 patent/US9539317B2/en active Active
-
2016
- 2016-12-14 US US15/378,294 patent/US10286059B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI0504945B1 (pt) | 2021-06-08 |
EP1989316B1 (en) | 2015-04-01 |
US20160367656A9 (en) | 2016-12-22 |
BRPI0504945A8 (pt) | 2015-12-22 |
WO2007051267A3 (en) | 2007-07-05 |
US20100297167A1 (en) | 2010-11-25 |
US20170157237A1 (en) | 2017-06-08 |
WO2007051267A2 (en) | 2007-05-10 |
US9539317B2 (en) | 2017-01-10 |
EP1989316A2 (en) | 2008-11-12 |
EP1989316A4 (en) | 2011-01-05 |
US10286059B2 (en) | 2019-05-14 |
WO2007051267A8 (en) | 2007-08-30 |
BRPI0504945A (pt) | 2007-08-07 |
US8828687B2 (en) | 2014-09-09 |
US20150024003A1 (en) | 2015-01-22 |
US20170360916A9 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0504945B8 (pt) | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. | |
BR112018012962A2 (pt) | vacinas de zika recombinantes | |
Donald et al. | The barley stripe mosaic virus 58-kilodalton beta (b) protein is a multifunctional RNA binding protein | |
NZ586238A (en) | Methods and compositions for immunizing pigs against porcine circovirus | |
BR9812845A (pt) | Circovìrus suìnos, vacinas e reagentes de diagnóstico | |
MXPA02005525A (es) | Clones infecciosos. | |
BR0312173A (pt) | Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante | |
Graff et al. | Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation | |
US20130071429A1 (en) | Bunyavirus vaccine | |
EP2618841B1 (en) | Bvdv vaccine | |
US11136355B2 (en) | Non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) and methods of using | |
JP2021534182A (ja) | 免疫原性組成物及びその使用 | |
EP3158060B1 (en) | Method for rapid generation of an infectious rna virus | |
Zulperi et al. | Sequence and phylogenetic analysis of S1, S2, M, and N genes of infectious bronchitis virus isolates from Malaysia | |
BRPI0904020B8 (pt) | composição vacinal contra o vírus da dengue, e, kit | |
Kuznetsova et al. | Adaptive mutation in nuclear export protein allows stable transgene expression in a chimaeric influenza A virus vector | |
MX2022016287A (es) | Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas. | |
KR20150137085A (ko) | 안정화된 fmdv 캡시드 | |
US20220088169A1 (en) | Virus vaccine | |
Guo et al. | Recombinant adenovirus expression of FMDV P1-2A and 3C protein and its immune response in mice | |
Zheng et al. | A simple method for developing an infectious cDNA clone of Japanese encephalitis virus | |
US20140024081A1 (en) | Methods and Compositions for Dengue Virus 3 (DV3) Infectious Clone | |
Nüesch et al. | Proteins specifically binding to the 3′ untranslated region of hepatitis A virus RNA in persistently infected cells | |
WO2002068662A8 (en) | Plasmid originated from bifidobacterium, recombinant expression vector using the plasmid and transformation method | |
Britton et al. | The use of PCR genome mapping for the characterisation of TGEV strains |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 15/66 , C12N 15/86 Ipc: C12N 15/66 (2006.01), C12N 15/86 (2006.01), C12N 1 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFICACAO DA PUBLICACAO DEVIDO A INCORRECOES NO TITULO DO RELATORIO DE EXAME TECNICO E NO QUADRO 1 DO PARECER DE DEFERIMENTO. |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFICACAO DO QUADRO 1 DO PARECER DE DEFERIMENTO. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2631 DE 08/06/2021 QUANTO AO QUADRO REIVINDICATORIO E AOS DESENHOS. |